TAGRISSO (osimertinib)

TAGRISSO is an EGFR TKI indicated as a monotherapy for:

Prescribing information

Indications

TAGRISSO as monotherapy is indicated for:1

  • the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
  • the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.